Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q6NUT2
UPID:
D19L2_HUMAN
Alternative names:
Dpy-19-like protein 2; Protein dpy-19 homolog 2
Alternative UPACC:
Q6NUT2; A4FVC1; B4E191; Q3ZCX2; Q6UWG8; Q96LZ9
Background:
The Probable C-mannosyltransferase DPY19L2, also known as Dpy-19-like protein 2 or Protein dpy-19 homolog 2, plays a crucial role in human biology. It is primarily involved in the C-mannosylation of tryptophan residues on target proteins. This enzyme is essential during spermatogenesis, facilitating sperm head elongation and acrosome formation, as well as acrosome attachment to the nuclear envelope. Its unique functions underscore its importance in reproductive biology.
Therapeutic significance:
Given its pivotal role in spermatogenesis, particularly in sperm head elongation and acrosome formation, DPY19L2 is directly linked to Spermatogenic failure 9, a disorder characterized by infertility due to spermatogenesis defects. Understanding the role of DPY19L2 could open doors to potential therapeutic strategies for treating infertility issues related to spermatogenesis defects.